Literature DB >> 21711238

The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation.

Mario Del Rosso1, Francesca Margheri, Simona Serratì, Anastasia Chillà, Anna Laurenzana, Gabriella Fibbi.   

Abstract

The urokinase plasminogen activator (uPA) and its receptor (uPAR) provide a cell surface integrated multimolecular complex that exerts pleiotropic functions influencing the development of inflammatory, immune, coagulation and fibrinolytic responses. Here we review the evidences indicating a role of the uPA/uPAR system in the regulation of the innate immune system in the inflammation process, of the adaptive immune response, as well as the role of fibrin and fibrin degradation products at the cross-road between coagulation and inflammation. Comparative studies have clearly highlighted the notion that coagulation and immunity are co-regulated and intertwined. The implication is that the vertebrate blood clotting system is evolutionarily by product of the innate immune system, where the blood clotting proteases have diverged from those comprising the complement system. Differences have emerged gradually, as shown by the acquisition of unique protein structures, such as kringle domains and gla (glutammic acid) domains, in order to comply with the increasingly complex vertebrate systems and to defend higher organisms against a range of infections and injuries. Plasminogen activation also controls the formation of complement anaphylotoxins (responsibe for vasodilatation, increase of venular permeability and leukocyte chemotaxis) and of bradykinin (which accounts for vasodilatation, increase of venular permeability and pain) by regulating the plasma contact system. The urokinase plasminogen activator and its cellular receptor, expressed on the surface of human leukocytes, provide a functional unit that, by regulating interaction of leukocytes with extracellular matrix, as well as its degradation, is critical for the migration of leukocytes and for their movement in the damaged tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21711238     DOI: 10.2174/138161211796718189

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  36 in total

1.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

Review 2.  Alcohol abuse and disorder of granulopoiesis.

Authors:  Xin Shi; Angelo L DeLucia; Jianxin Bao; Ping Zhang
Journal:  Pharmacol Ther       Date:  2019-03-01       Impact factor: 12.310

3.  Proteomic identification of VEGF-dependent protein enrichment to membrane caveolar-raft microdomains in endothelial progenitor cells.

Authors:  Anastasia Chillà; Francesca Magherini; Francesca Margheri; Anna Laurenzana; Tania Gamberi; Luca Bini; Laura Bianchi; Giovanna Danza; Benedetta Mazzanti; Simona Serratì; Alessandra Modesti; Mario Del Rosso; Gabriella Fibbi
Journal:  Mol Cell Proteomics       Date:  2013-04-09       Impact factor: 5.911

4.  Role of integrins in regulating proteases to mediate extracellular matrix remodeling.

Authors:  Jiao Yue; Kun Zhang; Jianfeng Chen
Journal:  Cancer Microenviron       Date:  2012-03-22

5.  BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.

Authors:  George S Karagiannis; Hara Afaloniati; Elisavet Karamanavi; Theofilos Poutahidis; Katerina Angelopoulou
Journal:  Tumour Biol       Date:  2015-09-10

Review 6.  Physiology and pathophysiology of the plasminogen system in the kidney.

Authors:  Per Svenningsen; Gitte Rye Hinrichs; Rikke Zachar; Rikke Ydegaard; Boye L Jensen
Journal:  Pflugers Arch       Date:  2017-06-27       Impact factor: 3.657

7.  Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.

Authors:  Tomohiro Fujisaka; Shu-Ichi Fujita; Daichi Maeda; Kensaku Shibata; Hideaki Takahashi; Hideaki Morita; Yoshihiro Takeda; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  Heart Vessels       Date:  2017-06-06       Impact factor: 2.037

8.  Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells.

Authors:  Qin Wang; Yunshan Wang; Yi Zhang; Yuke Zhang; Wei Xiao
Journal:  Lab Invest       Date:  2015-02-23       Impact factor: 5.662

9.  Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Authors:  Tariq U Azam; Husam R Shadid; Pennelope Blakely; Patrick O'Hayer; Hanna Berlin; Michael Pan; Peiyao Zhao; Lili Zhao; Subramaniam Pennathur; Rodica Pop-Busui; Izzet Altintas; Jens Tingleff; Marius A Stauning; Ove Andersen; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Pinkus Tober-Lau; Eleni Arnaoutoglou; Verena Keitel; Frank Tacke; Athanasios Chalkias; Sven H Loosen; Evangelos J Giamarellos-Bourboulis; Jesper Eugen-Olsen; Jochen Reiser; Salim S Hayek
Journal:  J Am Soc Nephrol       Date:  2020-09-22       Impact factor: 10.121

10.  Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

Authors:  Cláudia Viegas; Augusto J de Matos; Liliana R Leite-Martins; Inês Viegas; Rui R F Ferreira; Hugo Gregório; Andreia A Santos
Journal:  Can J Vet Res       Date:  2020-01       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.